CancerTME Pharma gets FDA Fast Track for Gliobla... TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination … more ➔
financingForbion participates in US financing round... Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. … more ➔
Clinical trialsNew law to speed up clinical trialsWith a new law, the German government wants to increase the number of clinical trials conducted in Germany and make the country number one in Europe again. more ➔
autoimmune diseaseGut bacteria seed autoimmunity-inducersA bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system. more ➔
Cultivated FoodInnocent Meat bags €3m financingCultivated meat producer Innocent Meat GmbH has cashed in €3m in funding from Venture Capital Fonds MV and an anonymous business angel. more ➔
NeurologySpanish Ferrer SA pays €122.5m for ALS...Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment. more ➔
acquisitionNovo Nordisk to acquire Cardior Pharmaceut... Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments. more ➔
Rare diseaseNDM Pharma provides POC for NMD670Researchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis. more ➔
gene therapyRoche opens €90m gene therapy developmen...Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich. more ➔
acquisitionAstraZeneca to take over Fusion Therapeut...British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront. more ➔
